Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Malignant Melanoma

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 14 articles: HTML format Text format

Single Articles

April 2019
1. TUNCER E, Calcada RR, Zingg D, Varum S, et al
   SMAD signaling promotes melanoma metastasis independently of phenotype switching.
   J Clin Invest. 2019;130.
   PubMed     Text format     Abstract available
   
   
   March 2019
2. MCEVOY CR, Xu H, Smith K, Etemadmoghadam D, et al
   Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
   J Clin Invest. 2019;130.
   PubMed     Text format     Abstract available
   
   
   September 2018
3. HUBER V, Vallacchi V, Fleming V, Hu X, et al
   Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
   J Clin Invest. 2018 Sep 27. pii: 98060. doi: 10.1172/JCI98060.
   PubMed     Text format     Abstract available
   
   
   April 2018
4. NSENGIMANA J, Laye J, Filia A, O'Shea S, et al
   beta-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
   J Clin Invest. 2018 Apr 16. pii: 95351. doi: 10.1172/JCI95351.
   PubMed     Text format     Abstract available
   
   
   January 2018
5. VEATCH JR, Lee SM, Fitzgibbon M, Chow IT, et al
   Tumor infiltrating BRAFV600E-specific CD4 T cells correlated with complete clinical response in melanoma.
   J Clin Invest. 2018 Jan 23. pii: 98689. doi: 10.1172/JCI98689.
   PubMed     Text format     Abstract available
   
   
   December 2017
6. TAMIYA H, Kim H, Klymenko O, Kim H, et al
   SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
   J Clin Invest. 2017 Dec 11. pii: 95410. doi: 10.1172/JCI95410.
   PubMed     Text format     Abstract available
   
   
   
7. VENKATESAN AM, Vyas R, Gramann AK, Dresser K, et al
   Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.
   J Clin Invest. 2017 Dec 4. pii: 92513. doi: 10.1172/JCI92513.
   PubMed     Text format     Abstract available
   
   
   October 2017
8. ZHAN Y, Guo J, Yang W, Goncalves C, et al
   MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
   J Clin Invest. 2017 Oct 16. pii: 91258. doi: 10.1172/JCI91258.
   PubMed     Text format     Abstract available
   
   
   August 2017
9. JESCHKE J, Bizet M, Desmedt C, Calonne E, et al
   DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.
   J Clin Invest. 2017;127:3090-3102.
   PubMed     Text format     Abstract available
   
   
   
10. AYERS M, Lunceford J, Nebozhyn M, Murphy E, et al
    IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade.
    J Clin Invest. 2017;127:2930-2940.
    PubMed     Text format     Abstract available
    
    
    June 2017
11. SMITH TT, Moffett HF, Stephan SB, Opel CF, et al
    Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.
    J Clin Invest. 2017;127:2176-2191.
    PubMed     Text format     Abstract available
    
    
    May 2017
12. OLVEDY M, Tisserand JC, Luciani F, Boeckx B, et al
    Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
    J Clin Invest. 2017 May 2. pii: 91291. doi: 10.1172/JCI91291.
    PubMed     Text format     Abstract available
    
    
    April 2017
13. ANSA-ADDO EA, Zhang Y, Yang Y, Hussey GS, et al
    Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-beta signaling.
    J Clin Invest. 2017;127:1321-1337.
    PubMed     Text format     Abstract available
    
    
    September 2016
14. JANOWSKI AM, Colegio OR, Hornick EE, McNiff JM, et al
    NLRC4 suppresses melanoma tumor progression independently of inflammasome activation.
    J Clin Invest. 2016 Sep 12. pii: 86953. doi: 10.1172/JCI86953.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: